未登录

E

Erden Banoğlu

Gazi University

H指数:30

被引数:2,501

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Structural expansion of benzimidazole-based FLAP inhibitors: identification of dual-action agents targeting leukotriene biosynthesis and Cancer cell proliferation

苯并咪唑类FLAP抑制剂的构效关系扩展：鉴定靶向白三烯生物合成和癌细胞增殖的双功能药物

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2026-10-180

PRE

Unveiling the molecular dynamics of a nitrile-containing 5-lipoxygenase-activating protein antagonist in primary macrophages through Raman spectroscopy

通过拉曼光谱揭示含腈基的5-脂氧合酶激活蛋白拮抗剂在原代巨噬细胞中的分子动力学

IF0

2026-01-090

OAAI

Target-specific de novo design of drug candidate molecules with graph-transformer-based generative adversarial networks

基于图变换器生成对抗网络的靶点特异性药物候选分子从头设计

Nature Machine Intelligence

IF23.9

2025-09-150

PRE

Harnessing structure-activity relationships to repurpose the FLAP inhibitor BRP-7 into potent and selective sEH inhibitors

利用构效关系改造FLAP抑制剂BRP-7，使其成为强效且高选择性的sEH抑制剂

Bioorganic Chemistry

IF4.7

2025-09-150

PRE

Potent soluble epoxide hydrolase inhibitors based on thiazole-5-carboxamide structure with imidazolidinone moiety as a secondary pharmacophore

基于噻唑-5-甲酰胺结构并含有咪唑烷酮基团作为次级药效团的强效可溶性环氧水解酶抑制剂

Bioorganic Chemistry

IF4.7

2025-05-290

PRE

Isoxazole-pyrimidine derivatives as TACC3 inhibitors: A novel modality to targeted cancer therapy

异恶唑-嘧啶衍生物作为TACC3抑制剂：靶向癌症治疗的一种新策略

BIOORGANIC CHEMISTRY

IF4.7

2025-03-010

PRE

Novel Benzimidazole Derivatives as Potent Inhibitors of Microsomal Prostaglandin E2 Synthase 1 for the Potential Treatment of Inflammation, Pain, and Fever

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2024-12-020

PRE

Tirbanibulin (KX2-391) analog KX2-361 inhibits botulinum neurotoxin serotype A mediated SNAP-25 cleavage in pre- and post-intoxication models in cells

DRUG DEVELOPMENT RESEARCH

IF4.2

2024-08-210

OAAI

Identifying the interactome of TACC3, a major driver in aggressive cancer cells with centrosome amplification

CANCER RESEARCH

IF16.6

2024-05-020

PRE

Reactivation of mitotic arrest upon targeting TACC3 restores immunogenic cell death and T-DM1 response in HER2-positive breast cancer

CANCER RESEARCH

IF16.6

2024-04-051

PRE

Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer

CANCER RESEARCH

IF16.6

2024-02-063

OAAI

Substituted 1,2,4-Triazoles as Novel and Selective Inhibitors of Leukotriene Biosynthesis Targeting 5-Lipoxygenase-Activating Protein

IF4.3

2023-08-182

OAAI

Discovery of a novel and potent TACC3 protein-protein interaction inhibitor targeting highly aggressive cancers

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification

CELL DEATH AND DIFFERENTIATION

IF15.4

2023-03-0210

OAAI

Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors

IF4.3

2023-01-045

OAAI

The 1,2,3-triazole 'all-in-one' ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool

EXPERT OPINION ON DRUG DISCOVERY

IF4.9

2022-10-0545

PRE

Quinazoline-4(3H)-one-7-carboxamide Derivatives as Human Soluble Epoxide Hydrolase Inhibitors with Developable 5-Lipoxygenase Activating Protein Inhibition

IF4.3

2022-10-055

OAAI

Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with In Vitro Growth Inhibitory and In Vivo Antitumor Activity

IF4.3

2022-10-035

OAAI

Discovery and Optimization of Piperazine Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors

哌嗪脲衍生物作为可溶性环氧化物水解酶 (sEH) 抑制剂的发现和优化

IF3.4

2022-05-126

PRE

A Series of Thiadiazolyl-Benzenesulfonamides Incorporating an Aromatic Tail as Isoform-Selective, Potent Carbonic Anhydrase II/XII Inhibitors

IF3.4

2022-03-097

PRE